Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those &gt; 5%

dc.contributor.author	Reid, Michelle
dc.contributor.author	Balcı, Serdar
dc.contributor.author	Bağcı, Pelin
dc.contributor.author	Saka, Burcu
dc.date.accessioned	2025-10-28T07:31:37Z
dc.date.available	2025-10-28T07:31:37Z
dc.date.issued	2020
dc.identifier.issn	0023-6837
dc.identifier.uri	http://dspace.adiyaman.edu.tr:8080/xmlui/handle/20.500.12414/6797
dc.language.iso	en	tr
dc.publisher	ELSEVIER SCIENCE INC	tr
dc.title	Is It Justifiable to Move the Grade-1 Ki67 Index Cut-Off from 3% to 5% for Pancreatic Neuroendocrine Tumors as Has Been Proposed? The Cases That Fall to 3-5% Category Have Clinicopathologic Characteristics Closer to Those > 5%	tr
dc.type	Other	tr
dc.contributor.authorID	0000-0002-7852-3851	tr
dc.contributor.department	Emory Univ Hosp	tr
dc.contributor.department	Marmara Univ	tr
dc.contributor.department	Istanbul Medipol Univ	tr
dc.identifier.endpage	1673	tr
dc.identifier.issue	1	tr
dc.identifier.startpage	1673	tr
dc.identifier.volume	100	tr
dc.source.title	LABORATORY INVESTIGATION	tr